CDKN3 and gastric adenocarcinoma: CDKN3 has upregulated in bladder urothelial carcinoma, breast invasive carcinoma, cholangiocarcinoma, colorectal cancer, esophageal carcinoma, head and neck squamous cell carcinoma, liver hepatocellular carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, prostate adenocarcinoma, rectum adenocarcinoma, stomach adenocarcinoma, thyroid cancer, and uterine corpus endometrial carcinoma.